Aug. 30 at 8:25 PM
$SLDB if the FALCON Phase 1b trial returns strong data—showing robust Frataxin restoration in the brain (IDN) and heart (IV), a clean safety profile, and early functional stabilization—Solid Biosciences can leverage its existing regulatory tools:
Existing Designations: SGT-212 already holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA.
BTR / RMAT Designation Request: Following positive Phase 1 data, Solid would apply for Breakthrough Therapy Designation (BTD) or Regenerative Medicine Advanced Therapy (RMAT) designation.
Pivotal Phase 2 Conversion: With RMAT/BTD in hand, the FDA frequently allows biotechs to expand the Phase 1b trial directly into a single seamless Phase 1b/2 registration-enabling trial, or jump straight to a single small pivotal cohort using Frataxin expression as the primary surrogate endpoint for Accelerated Approval. Plz do DD! Imho super bullish case in making !!
